Helping investors discover, understand, and stay up-to-date on investment opportunities within the Psychedelic industry.
Performance of psychedelic public companies this past week.
Cybin ($CYBN) received IND clearance from the FDA for their Phase I/IIa first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog being developed as a potential treatment of major depressive disorder. Press Release
PharmaTher Holdings ($PHRM | $PHRRF) successfully completed their research study evaluating their patented hydrogel-forming microneedle patch, to deliver ketamine and KETABET as a potential treatment for depression and other indications. Press Release
Tryp Therapeutics ($TRYP | $TRYPF) filed a new provisional patent for the use of psilocybin as a treatment for binge eating disorder. Tryp is utilizing TRP-8802 to evaluate the use of psilocybin-related compounds in neuropsychiatric disorders. Press Release
Optimi Health ($OPTI | $OPTHF) entered into a supply agreement with SABI Mind, a clinic group providing psychedelic-assisted therapies. Optimi will provide SABI with supplies of GMP psilocybin and MDMA for use in psychedelic-assisted therapeutic protocols. Press Release
Ceruvia Lifesciences (Private)announced that the FDA has approved their IND application for a Phase II clinical trial to determine the efficacy and safety of synthetic psilocybin as a potential treatment for obsessive-compulsive disorder. Press Release
Mindset Pharma ($MSET | $MSSTF) developed a novel, patent-pending, intranasal platform formulation technology expected to deliver improved central nervous system penetration of psychedelic medicines. The formulation technology has the potential for a more efficient, safer, and more cost-effective treatment. Press Release
Field Trip Health ($FTRP) provided operational updates. Highlights included intentions to separate the Field Trip Discovery and Field Trip Health divisions into two independent public companies, granted a patent for the first novel psychedelic molecule in development, FT-104 and launched an advanced wellness platform for personalized, at-home psychedelic care. Press Release
Filament Health ($FH | $FLHLF) announced a private placement for gross proceeds up to C$2.5. Filament intends to use the growth capital for drug discovery and development and intellectual property initiatives. Press Release
Psyched Wellness ($PSYC | $PSYCF) announced that the initial pilot production run of their first-to-market AME-1 product, Calm, is scheduled for July 7th. Calm will be the first legal Amanita Muscaria mushroom product to be sold in North America. Press Release
Algernon Pharmaceuticals ($AGN | $AGNPF) announce the price of their previously announced public offering for gross proceeds of up to $2M. Algernon intends to use the growth capital to fund research and development programs. Press Release